Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.28 +0.30 (+0.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
31 32 Next >
2 Stocks Jumping in Thursday's Premarket Trading
Get an early start on the events of the day. 
Via The Motley Fool
Sanofi, Provention Bio Ink Co-Promotion Pact For Type 1 Diabetes Treatment Candidate
Via Benzinga
Sanofi In-Licenses Preclinical Genetic Disease Candidate From An Unknown Biotech
Via Benzinga
Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis
Via Benzinga
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
Though successful in early testing, it wasn't enough to win a Phase 3 study. 
Via Investor's Business Daily
NASDAQ:SNY Investor Alert: Investigation over Potential Wrongdoing at Sanofi
San Diego, CA -- (SBWIRE) -- 09/20/2022 -- An investigation on behalf of investors in shares of Sanofi (NASDAQ:SNY) was announced over potential breaches of fiduciary duties by certain directors at... 
Via SBWire
Sanofi's Rare Disease Drug Xenpozyme Scores FDA Approval
Via Benzinga
Sanofi's Hemophilia Candidate Goes Under Priority FDA Review
Via Benzinga
TG Therapeutics Touts Encouraging Data From Multiple Sclerosis Candidate
Via Benzinga
Haleon Shares Pop After Rejecting Zantac Indemnification Requests From GSK, Pfizer
Via Benzinga
Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger
Via Benzinga
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing
Via Benzinga
ASLAN Pharma Starts Eblasakimab Program In Dupixent Treated Dermatitis Patients
Via Benzinga
Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease
Via Benzinga
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report
Via Benzinga
Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids
Via Benzinga
Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash...
Wall Street Journal 
Via Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 63 companies set new 52-week lows. 
Via Benzinga
Upstart Digital Health Company, DarioHealth, Announces Significant Contract with National Health Plan Provider, Giving Millions Access to Mental Health Resources
DarioHealth Corp. (NASDAQ: DRIO) recently announced 
Via Benzinga
MarketBeat: Week in Review 8/15 - 8/19
The economic reports continue to signal volatility. You can count on MarketBeat analysts to bring you the stocks and stories that are driving the market. 
Via MarketBeat
Topics Economy Workforce
Exposures Economy Interest Rates Layoff
Is Sanofi A Buy, Despite Recent Stumbles?
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
By Mark Gilman -- Benzinga 
Via News Direct
Exposures Product Safety
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
Americans with diabetes have been relying on insulin injections to manage their illness for decades. Those injections can be painful, expensive and inconvenient. The daily invasive testing regimen adds... 
Via TheNewswire.com
Exposures Product Safety
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 62 companies set new 52-week lows. 
Via Benzinga
Sanofi's Breast Cancer Drug Fallout 'Creates Buying Opportunity' For This Stock
According to Oppenheimer analyst, the fallout of Sanofi SA's (NASDAQ: SNY) amcenestrant creates a buying opportunity for Arvinas Inc (NASDAQ: ARVN)  
Via Benzinga
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
Americans with diabetes have been relying on insulin injections to manage their illness for decades. Those injections can be painful, expensive and inconvenient. The daily invasive testing regimen adds... 
Via Benzinga
Sanofi Earns Price Target Cut After Stopping Breast Cancer Drug Trial
Via Benzinga
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
Gainers 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.